Ablynx adds Sanofi to its list of pharma partners

Despite the large difference between upfront sum and total deal value, the research collaboration and global exclusive licensing agreement with Sanofi is Ablynx's second largest regarding upfront payments. On top of the list is the 2013 deal between Ablynx and pharma partner Abbvie with US$175m. But whereas Abbvie had secured access to a defined Phase III-ready Nanobody, the scope of the Sanofi deal is completely different. The collaboration gives Sanofi access to certain – but unspecified – Nanobodies in Ablynx's existing portfolio as well as access to Ablynx’s scientists and proprietary Nanobody platform. More specifically, Sanofi gains exclusive global rights to certain multi-specific Nanobodies against selected targets, with options for similar rights to additional targets. Sanofi could receive up to eight potential Nanobody product candidates.

To further improve the therapeutic potential of their proprietary Nanobodies, Ablynx develops multi-targeting versions. Linking different Nanobodies in one Nanobody construct – as a kind of combination therapy – might result in improved therapeutic effects.

The financial terms include an upfront payment of €23m to Ablynx, comprised of license and option fees. In addition, Ablynx will receive research funding, estimated to amount to €8m for the initially selected targets. Sanofi will be responsible for the development, manufacturing, and commercialisation of any products resulting from this agreement. Ablynx will be eligible to receive payments of up to €2.4bn plus tiered royalties up to low double digits on the net sales of any future products.

© european-biotechnology.com/ml